ClinicalTrials.gg
Sign In

Drug

Embibatinib clinical trials

Also written HS-10382 and MK-4208.

studies test it
6
open now
4
in phase 3
1
first study started
2022

Keep track of what changes. Save the Embibatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Embibatinib
1

Development codes

HS-10382
4
MK-4208
3
TERN-701
2

Combined with it in one product

HS-10382+Flumatinib
1

Studies by the year they started

6 studies that test it; most in 2024 (2)

Studies that test Embibatinib, by start year
YearStudies
20221
20231
20242
20262

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
1
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4

Who runs them

Industry 6 · Other 0

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (3)

Often tested with

Tested in the same studies.

Flumatinib (1)

Studies

Open first, then newest update. How each study uses Embibatinib is read from its arms, and is right about nine times in ten.

Testing it · 6